Belgium vs Nepal: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Belgium
94.0%
in 2025
Nepal
94.0%
in 2025
Belgium rank
46th
Nepal rank
46th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Belgium
- Nepal
How they compare
Belgium currently reports 94.0% against 94.0% in Nepal, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Nepal ahead.
Belgium ranks 46th and Nepal ranks 46th of 194 countries.
Belgium has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Belgium | Nepal | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | β |
| 2010s | 74.9% | 29.6% | 45.3% | Belgium |
| 2020s | 94.0% | 87.5% | 6.5% | Belgium |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Belgium or Nepal?
- Belgium, at 94.0% against 94.0% in Nepal as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Belgium and Nepal?
- 0.0%, with Belgium ahead.
- How many years of comparable data are there for Belgium and Nepal?
- 18 years are reported by both, from 2008 to 2025.
- How do Belgium and Nepal rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Belgium ranks 46th and Nepal ranks 46th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.